- €2.12bn
- -€244.71m
- CH₣0.53m
- 91
- 66
- 47
- 81
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.68 | ||
| PEG Ratio (f) | 0.24 | ||
| EPS Growth (f) | 65.64% | ||
| Dividend Yield (f) | 7.13% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.9 | ||
| Price to Tang. Book | 0.9 | ||
| Price to Free Cashflow | 13.69 | ||
| Price to Sales | 7.39 | ||
| EV to EBITDA | -0.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.63% | ||
| Return on Equity | 5.64% | ||
| Operating Margin | 46.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 728.17 | 741.78 | -343.59 | 1.26 | 0.53 | 124.5 | 134.25 | -37.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +2.04 | n/a | n/a | n/a | n/a | +12.71 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Directors
- Erich Hunziker CHM (67)
- Clive Meanwell VCH (62)
- Tanja Chicherio DMK
- Silvia Siegfried-Schanz DIR
- Maria-Grazia Iten-alderuccio DIR
- Claude Mikkelsen DIR
- Maurizio Bernasconi OTH
- Samuel Croset OTH
- Felicia Flanigan OTH
- Christian Koch OTH
- Daniel Koller OTH (50)
- Stephen Taubenfeld OTH
- Dallas Webb OTH
- Susan Galbraith DRC
- Mads Thomsen DRC
- Thomas von Planta DRC (59)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 10th, 1993
- Public Since
- November 8th, 2006
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 54,826,000
- Address
- Schwertstrasse 6, SCHAFFHAUSEN, 8200
- Web
- https://www.bbbiotech.ch/
- Phone
- +41 526240845
- Contact
- Claude Mikkelsen
- Auditors
- Deloitte AG
Latest News for BBZA
Upcoming Events for BBZA
Q4 2024 BB Biotech AG Earnings Release
BB Biotech AG Annual Shareholders Meeting
BB Biotech AG Annual Shareholders Meeting
Q1 2025 BB Biotech AG Earnings Release
Similar to BBZA
FAQ
As of Today at 18:32 UTC, shares in BB Biotech AG are trading at €39.35. This share price information is delayed by 15 minutes.
Shares in BB Biotech AG last closed at €39.35 and the price had moved by -0.38% over the past 365 days. In terms of relative price strength the BB Biotech AG share price has underperformed the FTSE Global All Cap Index by -13.53% over the past year.
The overall consensus recommendation for BB Biotech AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe BB Biotech AG dividend yield is 5.39% based on the trailing twelve month period.
Last year, BB Biotech AG paid a total dividend of CH₣2.00, and it currently has a trailing dividend yield of 5.39%. We do not have any data on when BB Biotech AG is to next pay dividends.
We do not have data on when BB Biotech AG is to next pay dividends. The historic dividend yield on BB Biotech AG shares is currently 5.39%.
To buy shares in BB Biotech AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €39.35, shares in BB Biotech AG had a market capitalisation of €2.12bn.
Here are the trading details for BB Biotech AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: BBZA
Based on an overall assessment of its quality, value and momentum BB Biotech AG is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BB Biotech AG is €60.84. That is 54.62% above the last closing price of €39.35.
Analysts covering BB Biotech AG currently have a consensus Earnings Per Share (EPS) forecast of CH₣3.46 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BB Biotech AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -9.96%.
As of the last closing price of €39.35, shares in BB Biotech AG were trading -9.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BB Biotech AG PE ratio based on its reported earnings over the past 12 months is 9.68. The shares last closed at €39.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BB Biotech AG's management team is headed by:
- Erich Hunziker - CHM
- Clive Meanwell - VCH
- Tanja Chicherio - DMK
- Silvia Siegfried-Schanz - DIR
- Maria-Grazia Iten-alderuccio - DIR
- Claude Mikkelsen - DIR
- Maurizio Bernasconi - OTH
- Samuel Croset - OTH
- Felicia Flanigan - OTH
- Christian Koch - OTH
- Daniel Koller - OTH
- Stephen Taubenfeld - OTH
- Dallas Webb - OTH
- Susan Galbraith - DRC
- Mads Thomsen - DRC
- Thomas von Planta - DRC